HTLV-1: epidemiology and pathogenesis of tropical spastic paraparesis/HTLV-1 associated myelopathy by Antoine Gessain
BioMed Central
Page 1 of 1
(page number not for citation purposes)
BMC Proceedings
Open AccessOral presentation
HTLV-1: epidemiology and pathogenesis of tropical spastic 
paraparesis/HTLV-1 associated myelopathy
Antoine Gessain
Address: Unité d'Epidémiologie et Physiopathologie des Virus Oncogènes, CNRS URA 3015 and Department of Virology, Institut Pasteur, 75724 
Paris Cedex 15, France
Email: Antoine Gessain - agessain@pasteur.fr
The association between the oncogenic human retrovirus
HTLV-1 and a form of tropical spastic paraparesis (TSP) of
unknown etiology (frequent in French West-Indies) was
demonstrated by our laboratory in 1985. A year later, the
association of HTLV-1 with a chronic spastic myelopathy
was documented in Southern Japan, and this clinical
entity was named HTLV-1 associated myelopathy (HAM).
It was then recognized that HTLV-1 associated TSP and
HAM were the same disease, the hybrid term TSP/HAM
was adopted and WHO diagnostic criteria were estab-
lished.
TSP/HAM is a chronic spastic paraparesis with signs of
bilateral pyramidal tract lesions and minor sensory signs.
The onset is insidious with gait disturbance, the evolution
is slowly progressive with no remission and after 10 years
of evolution, roughly 50% of the patients are wheel
chaired. The incubation period, between the primary
infection and the onset of the myelopathy signs, ranges
usually from years to decades, but TSP/HAM also devel-
oped within 3.3 years in 50% of the post transfusion-asso-
ciated cases.
Biologically, high levels of antibodies, directed against
HTLV-1, are present both in blood and CSF with intrathe-
cal production of specific antibody index. A high HTLV-1
proviral load is frequently observed in the PBL. Multiple
spotty high intensities in deep and sub-cortical areas on
T2-weighted images are the most frequent findings in
brain MRI. A mild atrophy of the thoracic spinal cord can
also be observed. On a pathological point of view, there is
a chronic inflammation with perivascular lymphocytic
cuffing and mild parenchymal lymphocytic infiltrates.
The cells are mostly CD4+ in early disease and mostly
CD8+ in latter disease. Pyramidal tract damage with mye-
lin and axonal loss, mainly in the lower thoracic spinal
cord are observed.
The pathogenesis of TSP/HAM is still poorly understood
and viral and host factors as the proviral load and the
immune response are considered to play a major role in
disease progression. At least three mechanisms have been
proposed to explain the HTLV-1 role in TSP/HAM devel-
opment.
The long-term prognosis of TSP/HAM remains severe with
a chronic evolution of a progressive disabling disorder
without remission. Globally, few short-term benefits of
therapeutic regimens have been observed, especially in
early disease, but no treatment has been successful in
chronic advanced disease. Failure to detect any clinical
improvement is believed to be due to irreversible central
nervous system damage in such patients. New controlled
studies of both antiviral and anti-inflammatory agents are
urgently required.
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